Beta-containing COVID-19 booster vaccine found to cross-neutralize

A new paper presents preliminary evidence that a new vaccine candidate, designed to boost immunity in already immunized individuals, and containing the adjuvanted Beta spike variant protein antigen, can induce a potent cross-neutralizing antibody response in non-human primate models that is detectable for up to three months.

Comparison of Omicron breakthrough infection versus monovalent SARS-CoV-2 intramuscular booster reveals differences in mucosal and systemic humoral immunity - Mucosal Immunology

Dean Huang's Instagram, Twitter & Facebook on IDCrawl

Protein-based SARS-CoV-2 spike vaccine booster increases cross- neutralization against SARS-CoV-2 variants of concern in non-human primates

The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants - ScienceDirect

In search of a pan-coronavirus vaccine: next-generation vaccine design and immune mechanisms

mutI-tri-RBD induced significantly higher titer of neutralizing

UB-612 vaccine booster found to elicit high neutralizing antibody levels against SARS-CoV-2 Omicron

Antibody affinity and cross-variant neutralization of SARS-CoV-2 Omicron BA.1, BA.2 and BA.3 following third mRNA vaccination

Beta-spike-containing boosters induce robust and functional antibody responses to SARS-CoV-2 in macaques primed with distinct vaccines - ScienceDirect

Frontiers Neutralization of SARS-CoV-2 Variants by mRNA and Adenoviral Vector Vaccine-Elicited Antibodies